Comparison of the hemoglobin adducts formed by administration of N-methylolacrylamide and acrylamide to rats.
Acrylamide (AM) and N-methylolacrylamide (NMA) are used in the formulation of grouting materials. AM undergoes metabolism to a reactive epoxide, glycidamide (GA). Both AM and GA react with hemoglobin to form adducts that can be related to exposure to AM. The objective of this study was to evaluate the extent to which NMA could form the same adducts as AM. N-(2-carbamoylethyl)valine (AAVal derived from AM) and N-(2-carbamoyl-2-hydroxyethyl)valine (GAVal derived from GA) were measured following a single oral dose of AM (50 mg/kg) or NMA (71 mg/kg) in male F344 rats. AAVal and GAVal were measured by a modified Edman degradation to produce phenylthiohydantoin derivatives and liquid chromatography/tandem mass spectrometry. In AM-treated rats, AAVal was 21 +/- 1.7-pmol/mg globin (mean +/- SD, n = 4), and GAVal was 7.9 +/- 0.8 pmol/mg. In NMA-treated rats, AAVal was 41 +/- 4.9 pmol/mg, and GAVal was 1.4 +/- 0.1 pmol/mg. Whether AAVal was derived from reaction of NMA with globin followed by loss of the hydroxymethyl group, or loss of the hydroxymethyl group to form AM prior to reaction with globin, is not known. However, the higher ratio of AAVal:GAVal in NMA-treated rats (29 vs. 2.6 in AM-treated rats) suggests that reaction of NMA with globin is the predominant route to AAVal in NMA-treated rats. The detection of GAVal in NMA-treated rats indicates oxidation of NMA, either directly or following conversion to AM. The lower levels of GAVal on NMA administration suggest that a much lower level of epoxide was formed than compared with AM treatment.
Fennell
Timothy R
TR
CIIT Centers for Health Research, P.O. Box 12137, Research Triangle Park, North Carolina 27709, USA. fennell@rti.org
Snyder
Rodney W
RW
Krol
Wojciech L
WL
Sumner
Susan C J
SC
D020106:Acrylamide / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D000178:Acrylamides / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism* / Q000633:toxicity; D000284:Administration, Oral; D000818:Animals; D002853:Chromatography, Liquid; D004852:Epoxy Compounds / Q000378:metabolism; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D013058:Mass Spectrometry; D051381:Rats; D011916:Rats, Inbred F344; D014633:Valine / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism
D000178:Acrylamides; D004852:Epoxy Compounds; D006454:Hemoglobins; C411702:N-(2-carbamoyethyl)valine; D020106:Acrylamide; C071834:glycidamide; D014633:Valine; C066443:N-methylolacrylamide